Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023.
- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023.
- This year’s awardees are financial executives at the forefront of the rapid technological development occurring throughout Houston across key global industries, including energy, life sciences, manufacturing, logistics and aerospace.
- “I am proud of Frank’s accomplishments at Castle,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
- Prior to joining Castle, Stokes served as chief financial officer for Hammock Pharmaceuticals, and as a managing director of Leerink Swann (now SVB Leerink), Robert W. Baird & Co.